INT128563

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2005
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 8
Total Number 9
Disease Relevance 6.70
Pain Relevance 5.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (Mllt1) nucleus (Mllt1) cytoplasm (Mllt1)
Anatomy Link Frequency
fat 2
superior 1
duodenum 1
Mllt1 (Mus musculus)
Pain Link Frequency Relevance Heat
Lamotrigine 753 100.00 Very High Very High Very High
Bioavailability 4 100.00 Very High Very High Very High
antiepileptic Drug 140 99.52 Very High Very High Very High
Neuropathic pain 6 98.00 Very High Very High Very High
fluoxetine 2 97.60 Very High Very High Very High
carbamazepine 77 97.40 Very High Very High Very High
antidepressant 1 95.04 Very High Very High Very High
cocaine 6 92.52 High High
addiction 6 92.20 High High
anticonvulsant 24 67.52 Quite High
Disease Link Frequency Relevance Heat
Exanthema 110 99.84 Very High Very High Very High
Convulsion 266 99.64 Very High Very High Very High
Epilepsy 84 99.34 Very High Very High Very High
Vomiting 46 99.28 Very High Very High Very High
Dizziness 28 99.04 Very High Very High Very High
Manic Depressive Disorder 6 98.84 Very High Very High Very High
Diplopia 20 98.82 Very High Very High Very High
Ataxia 20 98.62 Very High Very High Very High
Syndrome 60 98.60 Very High Very High Very High
Neuropathic Pain 6 98.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For instance, LTG monotherapy was found to be superior to LTG + CBZ in drug-refractory epilepsy29 and LTG + VPA or topiramate was evidently synergistic in epileptic patients.30 Preclinical data on interactions of LTG with other AEDs are summarized in Table 1.
LTG Binding (interactions) of in superior associated with epilepsy, lamotrigine, antiepileptic drug and carbamazepine
1) Confidence 0.41 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 1.23 Pain Relevance 0.95
Among these, ataxia, diplopia, dizziness, and nausea were statistically more frequently associated with LTG.
LTG Binding (associated) of associated with ataxia, diplopia, vomiting, dizziness and lamotrigine
2) Confidence 0.41 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 1.64 Pain Relevance 0.61
g/mL are generally well tolerated.3 LTG is also indicated against generalized seizures in Lennox–Gastaut syndrome and has been approved for conversion to monotherapy.3 Interestingly, LTG has been found to be effective in treating bipolar disorder and neuropathic pain syndromes.3,20 More studies are necessary to evaluate its possible efficacy in the treatment of Alzheimer’s disease and cocaine addiction.20
LTG Binding (found) of associated with addiction, manic depressive disorder, convulsion, syndrome, neuropathic pain, lamotrigine, disease and cocaine
3) Confidence 0.32 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 0.82 Pain Relevance 0.61
LTG-XR, due to a special eroding matrix, considerably reduces the rate of LTG release over 12–15 h.3 An enteric coating additionally prevents LTG release which starts when a tablet passes to the duodenum.17

Pharmacokinetics of LTG-XR

LTG Binding (passes) of in duodenum associated with lamotrigine
4) Confidence 0.32 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 0.61 Pain Relevance 0.79
g/mL are generally well tolerated.3 LTG is also indicated against generalized seizures in Lennox–Gastaut syndrome and has been approved for conversion to monotherapy.3 Interestingly, LTG has been found to be effective in treating bipolar disorder and neuropathic pain syndromes.3,20 More studies are necessary to evaluate its possible efficacy in the treatment of Alzheimer’s disease and cocaine addiction.20
LTG Binding (indicated) of associated with addiction, manic depressive disorder, convulsion, syndrome, neuropathic pain, lamotrigine, disease and cocaine
5) Confidence 0.32 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 0.86 Pain Relevance 0.54
Werz3 reviewed the tolerability of LTG-IR and listed adverse effects which were found to be at least 3 percentage points higher in LTG-IR patients than in placebo patients and included: dizziness, diplopia, ataxia, nausea, blurred vision, somnolence, vomiting, abnormal coordination, tremor, insomnia, and rhinitis.
LTG Binding (tolerability) of associated with tremor, rhinitis, ataxia, diplopia, vomiting, dizziness, lamotrigine and sleep disorders
6) Confidence 0.32 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874338 Disease Relevance 1.43 Pain Relevance 0.92
LTG-XR has a modified-release eroding matrix to control its dissolution rate,16 which leads to changes in absorption rates (time to peak plasma concentration [Tmax] 1–1.5 hours for LTG-IR versus 4–11 hours for LTG-XR).17 Despite the changes in Tmax, the bioavailability of LTG-XR and LTG-IR is similar, except for patients taking enzyme-inducing antiepileptic drugs in whom the bioavailability of LTG-XR is 21% lower; the clinical importance of this finding is not clear.17 Its levels have been shown to be unaffected by high-fat meals, suggesting that the LTG-XR form is not significantly lipophilic. 18 Studies have shown that lamotrigine is eliminated via hepatic N2-glucuronidation.19
LTG-XR Neg (except) Binding (bioavailability) of in fat associated with lamotrigine, antiepileptic drug and bioavailability
7) Confidence 0.31 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998806 Disease Relevance 0.05 Pain Relevance 0.37
LTG-XR has a modified-release eroding matrix to control its dissolution rate,16 which leads to changes in absorption rates (time to peak plasma concentration [Tmax] 1–1.5 hours for LTG-IR versus 4–11 hours for LTG-XR).17 Despite the changes in Tmax, the bioavailability of LTG-XR and LTG-IR is similar, except for patients taking enzyme-inducing antiepileptic drugs in whom the bioavailability of LTG-XR is 21% lower; the clinical importance of this finding is not clear.17 Its levels have been shown to be unaffected by high-fat meals, suggesting that the LTG-XR form is not significantly lipophilic. 18 Studies have shown that lamotrigine is eliminated via hepatic N2-glucuronidation.19
LTG-IR Neg (except) Binding (bioavailability) of in fat associated with lamotrigine, antiepileptic drug and bioavailability
8) Confidence 0.31 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998806 Disease Relevance 0.05 Pain Relevance 0.37
Factors associated with a significantly higher LTG-CDR were: age > or =70 years, and cotreatment with valproate.
LTG-CDR Binding (associated) of
9) Confidence 0.29 Published 2005 Journal J Clin Psychopharmacol Section Abstract Doc Link 16012277 Disease Relevance 0 Pain Relevance 0.46

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox